mitoxantrone has been researched along with Granulocytic Leukemia, Chronic in 41 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and toxicity of carboplatin plus mitoxantrone in blast crisis of chronic myeloid leukemia (CMLBC) were evaluated." | 9.14 | A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. ( Dutcher, JP; Gaynor, B; Morris, EL; Paietta, E; Wiernik, PH, 2010) |
| "To ascertain the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with mitoxantrone at 12 mg/m(2) daily for 3 days in the treatment of acute leukemia." | 9.10 | Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. ( Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hurwitz, H; Jacobson, R; Laughlin, MJ; Moore, JO; Petros, WP; Rizzieri, DA; Rosner, GL, 2002) |
| "In an effort to determine if cell cycle active agents are augmented when given after non-cell cycle active agents, 104 patients with either multiply relapsed or refractory acute nonlymphocytic leukemia or blast crisis of chronic myelogenous leukemia were treated with mitoxantrone." | 9.07 | Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. ( Bennett, J; Browman, G; Bryant, J; Goldberg, J; Grunwald, H; Gryn, J; Larson, R; Preisler, H; Raza, A; Vogler, R, 1993) |
| "The efficacy and toxicity of carboplatin plus mitoxantrone in blast crisis of chronic myeloid leukemia (CMLBC) were evaluated." | 5.14 | A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. ( Dutcher, JP; Gaynor, B; Morris, EL; Paietta, E; Wiernik, PH, 2010) |
| "To ascertain the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with mitoxantrone at 12 mg/m(2) daily for 3 days in the treatment of acute leukemia." | 5.10 | Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. ( Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hurwitz, H; Jacobson, R; Laughlin, MJ; Moore, JO; Petros, WP; Rizzieri, DA; Rosner, GL, 2002) |
| "Cytarabine is an essential drug for inducing remission of acute myelogenous leukemia, and it is also one the most effective drugs used as salvage therapy for patients with all types of relapsed acute leukemia." | 5.09 | A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. ( Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB, 1999) |
| "In an effort to determine if cell cycle active agents are augmented when given after non-cell cycle active agents, 104 patients with either multiply relapsed or refractory acute nonlymphocytic leukemia or blast crisis of chronic myelogenous leukemia were treated with mitoxantrone." | 5.07 | Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. ( Bennett, J; Browman, G; Bryant, J; Goldberg, J; Grunwald, H; Gryn, J; Larson, R; Preisler, H; Raza, A; Vogler, R, 1993) |
| "In a phase I study, 68 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and accelerated- and blastic-phase CML received induction therapy consisting of cytarabine 3 g/m2 by infusion over 3 hours daily for 5 days, with escalating doses of mitoxantrone 40 to 80 mg/m2 over 1 to 2 days by intravenous infusion over 15 minutes." | 5.07 | Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. ( Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993) |
| "Fourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methylprednisolone 1000 mg/day intravenously for 5 days." | 2.70 | Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone. ( Ayyildiz, O; Bolaman, Z; Demir, S; Kadiköylü, G; Köseoğlu, M; Müftüoğlu, E; Sönmez, HM, 2002) |
| "A phase II clinical study was performed to evaluate the effectiveness and toxicity of cladribine (2-CdA) combined with mitoxantrone (CM regimen) in the treatment of chronic myeloid leukemia in blastic phase (CML BP)." | 2.70 | Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia. ( Góra-Tybor, J; Robak, T, 2001) |
| "The prognosis of blast crisis (BC) of chronic myelogenous leukemia (CML) is extremely poor despite many efforts to induce remission with chemotherapy." | 2.40 | Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate. ( Chiba, S; Hirai, H; Honda, H; Kanda, Y; Yazaki, Y, 1999) |
| "However, the case of secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation is rare." | 1.56 | Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report. ( Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W, 2020) |
| "However, therapy-related chronic myelogenous leukemia is relatively rare." | 1.40 | [Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma]. ( Hiroshima, Y; Ichikawa, N; Kirihara, T; Kobayashi, H; Kurihara, T; Mori, Y; Sato, K; Shibazaki, M; Sumi, M; Takeda, W; Ueki, T; Ueno, M, 2014) |
| "We report the first case of chronic myeloid leukemia (CML) in a patient with multiple sclerosis (MS) diagnosed within two years of receiving mitoxantrone therapy." | 1.35 | Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS. ( Rammal, M; Sadiq, SA; Sara, G, 2008) |
| "After each course, minimal residual disease was tested by specific reverse transcriptase-polymerase chain reaction (RT-PCR) (median sensitivity, 10(-5))." | 1.31 | Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. ( Bilhou-Nabera, C; Blaise, D; Boiron, JM; Boucheix, C; Bourhis, JH; Buzyn, A; Cayuela, JM; Charrin, C; Delannoy, A; Dombret, H; Espérou, H; Fegueux, N; Fenaux, P; Fière, D; Gabert, J; Lhéritier, V; MacIntyre, E; Rigal-Huguet, F; Thomas, X; Vernant, JP, 2002) |
| "We measured the percentage of Philadelphia chromosome (Ph)-negative cells in the autologous cells collected after conventional-dose chemotherapy-induced myelosuppression before autologous transplant and in the marrow of these same CML patients after autologous transplantation of these cells into recipients treated with the cyclophosphamide, VP-16, and TBI." | 1.29 | Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog ( Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P, 1995) |
| "Bepridil was identified predominantly in the octanol phase in the octanol/water partitioning studies." | 1.28 | Response of human chronic myeloid leukemia cells to mitoxantrone cytotoxicity: potentiation by bepridil, a calcium channel antagonist. ( Advani, SH; Chitnis, MP; Parekh, HK; Shallom, JM, 1991) |
| " In K562 the sequence Ara-C much greater than MX was significantly more toxic (3." | 1.28 | Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM. ( Büchner, T; Hiddemann, W; Krehmeier, C; Zühlsdorf, M, 1990) |
| "9 patients had acute myeloblastic leukemia (AML), (4 relapsed, 5 refractory), 20 had acute lymphoblastic leukemia (ALL) (11 relapsed, 9 refractory) and 6 had chronic myelogenous leukemia (CML) in the blastic phase (BP)." | 1.28 | High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. ( Carcassonne, Y; Gastaut, JA; Launay, MC; Lejeune, C; Maraninchi, D; Richard, B; Sainty, D; Sebahoun, G; Tubiana, N, 1990) |
| " The results indicate that reserpine enhances the cytotoxicity of mitoxantrone and adriamycin in mildly toxic concentrations (1 and 10 micrograms respectively), in CML cells." | 1.28 | Mitoxantrone & adriamycin cytotoxicity enhanced by reserpine in human chronic myeloid leukaemia cells. ( Advani, SH; Chitnis, MP; Kamath, NS, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.88) | 18.7374 |
| 1990's | 24 (58.54) | 18.2507 |
| 2000's | 11 (26.83) | 29.6817 |
| 2010's | 3 (7.32) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, J | 1 |
| Liao, Y | 1 |
| Bin, T | 1 |
| OUYang, J | 1 |
| Chen, S | 1 |
| Chen, X | 1 |
| Zou, W | 1 |
| Huang, FF | 1 |
| Zhang, L | 1 |
| Wu, DS | 1 |
| Yuan, XY | 1 |
| Yu, YH | 1 |
| Zhao, XL | 1 |
| Chen, FP | 1 |
| Zeng, H | 1 |
| Shibazaki, M | 1 |
| Sumi, M | 1 |
| Takeda, W | 1 |
| Kirihara, T | 1 |
| Kurihara, T | 1 |
| Sato, K | 1 |
| Ueki, T | 1 |
| Hiroshima, Y | 1 |
| Ueno, M | 1 |
| Ichikawa, N | 1 |
| Mori, Y | 1 |
| Kobayashi, H | 1 |
| Dutcher, JP | 2 |
| Morris, EL | 1 |
| Gaynor, B | 1 |
| Paietta, E | 2 |
| Wiernik, PH | 2 |
| Axdorph, U | 1 |
| Stenke, L | 1 |
| Grimfors, G | 1 |
| Carneskog, J | 1 |
| Hansen, J | 1 |
| Linder, O | 1 |
| Ljungman, P | 1 |
| Löfvenberg, E | 1 |
| Malm, C | 1 |
| Simonsson, B | 1 |
| Turesson, I | 1 |
| Vilén, L | 1 |
| Udén, AM | 1 |
| Björkholm, M | 2 |
| Dombret, H | 1 |
| Gabert, J | 1 |
| Boiron, JM | 1 |
| Rigal-Huguet, F | 1 |
| Blaise, D | 1 |
| Thomas, X | 1 |
| Delannoy, A | 1 |
| Buzyn, A | 1 |
| Bilhou-Nabera, C | 1 |
| Cayuela, JM | 1 |
| Fenaux, P | 1 |
| Bourhis, JH | 1 |
| Fegueux, N | 1 |
| Charrin, C | 1 |
| Boucheix, C | 1 |
| Lhéritier, V | 1 |
| Espérou, H | 1 |
| MacIntyre, E | 1 |
| Vernant, JP | 1 |
| Fière, D | 1 |
| Bolaman, Z | 1 |
| Köseoğlu, M | 1 |
| Ayyildiz, O | 1 |
| Kadiköylü, G | 1 |
| Sönmez, HM | 1 |
| Demir, S | 1 |
| Müftüoğlu, E | 1 |
| Fiser, K | 1 |
| Klamová, H | 1 |
| Moravcová, J | 1 |
| López-Lázaro, M | 1 |
| Pastor, N | 1 |
| Azrak, SS | 1 |
| Ayuso, MJ | 1 |
| Cortés, F | 1 |
| Austin, CA | 1 |
| Fruehauf, S | 1 |
| Topaly, J | 1 |
| Buss, EC | 1 |
| Fischer, T | 1 |
| Ottmann, OG | 1 |
| Emmerich, B | 1 |
| Müller, MC | 1 |
| Schuld, P | 1 |
| Balleisen, L | 1 |
| Hehlmann, R | 1 |
| Ho, AD | 1 |
| Hochhaus, A | 1 |
| Sadiq, SA | 1 |
| Rammal, M | 1 |
| Sara, G | 1 |
| Goldberg, J | 1 |
| Gryn, J | 1 |
| Raza, A | 1 |
| Bennett, J | 1 |
| Browman, G | 1 |
| Bryant, J | 1 |
| Grunwald, H | 1 |
| Larson, R | 1 |
| Vogler, R | 1 |
| Preisler, H | 1 |
| Talpaz, M | 2 |
| Kantarjian, H | 1 |
| Liang, J | 2 |
| Calvert, L | 2 |
| Hamer, J | 1 |
| Tibbits, P | 1 |
| Durett, A | 1 |
| Claxton, D | 1 |
| Giralt, S | 1 |
| Khouri, I | 1 |
| Kantarjian, HM | 2 |
| Hester, J | 1 |
| Feldman, E | 1 |
| Korbling, M | 1 |
| Rios, MB | 2 |
| Smith, TL | 1 |
| Deisseroth, AB | 1 |
| Liliemark, EK | 1 |
| Liliemark, J | 1 |
| Pettersson, B | 1 |
| Gruber, A | 2 |
| Peterson, C | 1 |
| Duru, F | 1 |
| Tuncer, M | 1 |
| Hiçsönmez, G | 1 |
| Feldman, EJ | 2 |
| Alberts, DS | 1 |
| Arlin, Z | 2 |
| Ahmed, T | 1 |
| Mittelman, A | 1 |
| Baskind, P | 1 |
| Peng, YM | 1 |
| Baier, M | 1 |
| Plezia, P | 1 |
| Sundman-Engberg, B | 1 |
| Tidefelt, U | 1 |
| Paul, C | 1 |
| Wei, CH | 1 |
| Yu, IT | 1 |
| Tzeng, CH | 1 |
| Fan, FS | 1 |
| Hsieh, RK | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Chen, PM | 1 |
| List, AF | 1 |
| Spier, CS | 1 |
| Grogan, TM | 1 |
| Johnson, C | 1 |
| Roe, DJ | 1 |
| Greer, JP | 1 |
| Wolff, SN | 1 |
| Broxterman, HJ | 1 |
| Scheffer, GL | 1 |
| Scheper, RJ | 1 |
| Dalton, WS | 1 |
| Lipton, JH | 1 |
| Messner, HA | 1 |
| Curtis, JE | 1 |
| Atkins, HL | 1 |
| Minden, MD | 1 |
| Martinelli, G | 1 |
| Testoni, N | 1 |
| Zuffa, E | 1 |
| Visani, G | 1 |
| Zinzani, PL | 1 |
| Zaccaria, A | 1 |
| Farabegoli, P | 1 |
| Arpinati, M | 1 |
| Amabile, M | 1 |
| Tura, S | 1 |
| Irving, JA | 1 |
| Finney, R | 1 |
| Lennard, A | 1 |
| Proctor, SJ | 1 |
| Nagler, A | 1 |
| Soni, S | 1 |
| Samuel, S | 1 |
| Or, R | 1 |
| Verfaillie, CM | 1 |
| Bhatia, R | 1 |
| Steinbuch, M | 1 |
| DeFor, T | 1 |
| Hirsch, B | 1 |
| Miller, JS | 1 |
| Weisdorf, D | 1 |
| McGlave, PB | 1 |
| Kanda, Y | 1 |
| Chiba, S | 1 |
| Honda, H | 1 |
| Hirai, H | 1 |
| Yazaki, Y | 1 |
| Koller, CA | 1 |
| O'Brien, S | 1 |
| Estey, E | 1 |
| Keating, M | 1 |
| Robak, T | 1 |
| Góra-Tybor, J | 1 |
| Hambach, L | 1 |
| Eder, M | 1 |
| Dammann, E | 1 |
| Battmer, K | 1 |
| Stucki, A | 1 |
| Heil, G | 1 |
| Ganser, A | 1 |
| Hertenstein, B | 1 |
| Rizzieri, DA | 1 |
| Bass, AJ | 1 |
| Rosner, GL | 1 |
| Gockerman, JP | 1 |
| DeCastro, CM | 1 |
| Petros, WP | 1 |
| Adams, DJ | 1 |
| Laughlin, MJ | 1 |
| Davis, P | 1 |
| Foster, T | 1 |
| Jacobson, R | 1 |
| Hurwitz, H | 1 |
| Moore, JO | 1 |
| Yamaguchi, H | 1 |
| Inokuchi, K | 1 |
| Yokomizo, E | 1 |
| Miyata, J | 1 |
| Watanabe, A | 1 |
| Inami, M | 1 |
| Tajika, K | 1 |
| Dan, K | 1 |
| Eudey, L | 1 |
| Bennett, JM | 1 |
| Kellermeyer, R | 1 |
| Rowe, J | 1 |
| O'Connell, M | 1 |
| Oken, M | 1 |
| Parekh, HK | 2 |
| Shallom, JM | 1 |
| Advani, SH | 4 |
| Chitnis, MP | 4 |
| Parekh, H | 1 |
| Chitnis, M | 1 |
| Hartley, JA | 1 |
| Forrow, SM | 1 |
| Souhami, RL | 1 |
| Reszka, K | 1 |
| Lown, JW | 1 |
| Krehmeier, C | 1 |
| Zühlsdorf, M | 1 |
| Büchner, T | 1 |
| Hiddemann, W | 1 |
| Linkesch, W | 1 |
| Thaler, J | 1 |
| Gattringer, C | 1 |
| Konwalinka, G | 1 |
| Lejeune, C | 1 |
| Tubiana, N | 1 |
| Gastaut, JA | 1 |
| Maraninchi, D | 1 |
| Richard, B | 1 |
| Launay, MC | 1 |
| Sainty, D | 1 |
| Sebahoun, G | 1 |
| Carcassonne, Y | 1 |
| Satyamoorthy, K | 1 |
| Pradhan, SG | 1 |
| Kamath, NS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4)[NCT00002700] | Phase 3 | 392 participants (Anticipated) | Interventional | 1995-08-31 | Completed | ||
| Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mitoxantrone and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Etoposide; Humans; | 1999 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation | 2001 |
Philadelphia chromosome-positive acute myeloid leukemia with tetraploidy.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Daunor | 2002 |
12 trials available for mitoxantrone and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carboplatin; Female; Foll | 2010 |
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Combined Moda | 2002 |
Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Humans; Leu | 2002 |
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; E | 2007 |
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.
Topics: Adult; Azacitidine; Biopsy; Blast Crisis; Bone Marrow; Cell Cycle; DNA, Neoplasm; Female; Humans; Ka | 1993 |
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Cr | 1993 |
Molecular remission in Philadelphia-positive adult acute lymphoblastic leukaemia rapidly induced by conventional-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Fa | 1998 |
Engraftment following mitoxantrone (Mito) based conditioning for allogeneic bone marrow transplantation (allo-BMT).
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Comb | 1998 |
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Cr | 1999 |
Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Blast Crisis; Cladribine; Drug Administration Schedule; Female; | 2001 |
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2002 |
Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Drug Evaluat | 1992 |
26 other studies available for mitoxantrone and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etopos | 2020 |
PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia.
Topics: Adult; Aged; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassett | 2014 |
[Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Huma | 2014 |
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Stu | 2002 |
Gene expression profiles of two accelerations in a CML patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Gene Expression Pro | 2006 |
Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.
Topics: Amsacrine; Antineoplastic Agents; Digitoxin; Dose-Response Relationship, Drug; Drug Screening Assays | 2006 |
Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.
Topics: Adult; Antineoplastic Agents; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mito | 2008 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Ce | 1995 |
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Separation; Cyt | 1995 |
In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Blood Proteins; Cytarabin | 1993 |
Prolonged hematological remission by mitoxantrone and interferon--alpha-2b in a child with resistant Philadelphia chromosome-positive chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Interferon alpha-2; Interferon-alpha; | 1993 |
Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo.
Topics: Adult; Aged; Aged, 80 and over; Blast Crisis; Female; Humans; Intracellular Fluid; Leukemia, Myeloge | 1993 |
Trisomy 21 in acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Down Syndrome; Humans; Hydroxyure | 1996 |
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antigens, CD7; Antineopla | 1996 |
Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post-remission bone marrow transplant--a pilot study.
Topics: Adolescent; Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone M | 1996 |
FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantati | 1996 |
Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1998 |
Response of human chronic myeloid leukemia cells to mitoxantrone cytotoxicity: potentiation by bepridil, a calcium channel antagonist.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bepridil; DNA, Neoplasm; Drug Synergism; Humans; Leu | 1991 |
Differential alteration of cellular lipids in drug sensitive and resistant P388 leukemia cells by clofibrate: effects on mitoxantrone cytotoxicity.
Topics: Animals; Cell Line; Clofibrate; DNA, Neoplasm; Doxorubicin; Drug Resistance; Humans; Leukemia P388; | 1991 |
Abrogation of human chronic myeloid leukemia cells insensitivity to adriamycin and mitoxanthrone cytotoxicity by quinidine.
Topics: Cell Survival; DNA Replication; DNA, Neoplasm; Doxorubicin; Humans; Kinetics; Leukemia, Myelogenous, | 1990 |
Photosensitization of human leukemic cells by anthracenedione antitumor agents.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Human | 1990 |
Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM.
Topics: Cells, Cultured; Cytarabine; Drug Administration Schedule; Drug Synergism; Hematopoietic Stem Cells; | 1990 |
Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemothe | 1990 |
High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.
Topics: Adolescent; Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Infusions, In | 1990 |
Modulation of mitoxantrone cytotoxicity by verapamil in human chronic myeloid leukemia cells.
Topics: DNA; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitoxantrone; Tumor C | 1989 |
Mitoxantrone & adriamycin cytotoxicity enhanced by reserpine in human chronic myeloid leukaemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Doxorubicin; Drug Screening Assays, A | 1989 |